Coverage
-
May 28, 2015
A California federal judge Wednesday tossed a derivative shareholder suit accusing Allergan Inc.'s board members of improperly marketing the cosmetic drug Botox for off-label uses after a voluntary dismissal by the plaintiffs, who the pharmaceutical giant argued no longer had standing following an acquisition by Actavis PLC.
1 other articles on this case.
View all »